News
Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.
Potential Positives. Kymera Therapeutics has successfully priced a public offering of $250.8 million, providing significant capital for further development and expansion of its pipeline.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback